Related Experiment Video

Updated: May 5, 2026

Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery
08:43

Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery

Published on: February 14, 2017

10.5K

HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway

S Dimmeler1, A Aicher, M Vasa

  • 1Division of Molecular Cardiology, Department of Medicine IV, University of Frankfurt, Frankfurt, Germany. Dimmeler@em.uni-frankfurt.de

The Journal of Clinical Investigation
|August 8, 2001
PubMed

Insights

Statins, used for lowering cholesterol, significantly boost the differentiation of endothelial progenitor cells (EPCs). This action, mediated by the PI3K/Akt pathway, may explain their cardiovascular benefits.

Area of Science:

  • Cardiovascular Science
  • Hematology
  • Molecular Biology

Background:

  • HMG-CoA reductase inhibitors (statins) are primary lipid-lowering agents proven to reduce cardiovascular disease morbidity and mortality.
  • Endothelial progenitor cells (EPCs) play a crucial role in vascular repair and neovascularization.

Purpose of the Study:

  • To investigate the effect of statins on endothelial progenitor cell differentiation.
  • To elucidate the molecular mechanisms underlying statin-induced EPC differentiation.

Main Methods:

  • Isolation of mononuclear cells and CD34-positive hematopoietic stem cells from peripheral blood.
  • Treatment of mice with statins and analysis of hematopoietic stem cell populations.
  • Assessment of the PI3K/Akt pathway involvement using pharmacological inhibitors and genetic constructs.

Main Results:

  • Statins potently augmented EPC differentiation in human cells and increased hematopoietic stem cells and differentiated EPCs in mice.
  • Statin-induced EPC differentiation was dependent on the PI3K/Akt pathway.
  • Vascular Endothelial Growth Factor (VEGF) also utilizes the Akt pathway to enhance EPC numbers.

Conclusions:

  • Statins significantly enhance EPC differentiation, potentially through the PI3K/Akt pathway.
  • Augmentation of circulating EPCs by statins may contribute significantly to their cardioprotective effects in coronary artery disease patients.

More Related Videos

Isolation of Endothelial Progenitor Cells from Human Umbilical Cord Blood07:26

Isolation of Endothelial Progenitor Cells from Human Umbilical Cord Blood

Published on: September 14, 2017

11.0K
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia07:25

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Published on: September 22, 2020

2.8K

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741